This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 15, 2006
Last updated: July 17, 2013
Last verified: August 2008

RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I/II trial is studying the side effects and best dose of VNP40101M and to see how well it works in treating patients with Richter syndrome or refractory or relapsed chronic lymphocytic leukemia or other lymphoproliferative disorders.

Condition Intervention Phase
Leukemia Lymphoma Drug: laromustine Phase 1 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I/II Study of Cloretazine in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia or Richter's Syndrome

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Maximum tolerated dose
  • Toxicity
  • Efficacy

Estimated Enrollment: 35
Study Start Date: July 2005
Study Completion Date: August 2008
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose (MTD) of VNP40101M in patients with Richter syndrome or refractory or relapsed chronic lymphocytic leukemia or other lymphoproliferative disease. (phase I)
  • Determine the toxic effects of this drug in these patients. (phase I)
  • Determine the efficacy, as determined by overall response rate, of this drug at the MTD determined in phase I in these patients. (phase II)

OUTLINE: This is a phase I dose-escalation study followed by a phase II study.

  • Phase I: Patients receive VNP40101M IV over 30 minutes on day 1. Courses repeat every 3-6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of VNP40101M until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

  • Phase II: Patients receive VNP40101M at the MTD determined in phase I.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following hematologic malignancies:

    • Fludarabine refractory or relapsed chronic lymphocytic leukemia (CLL)

      • CLL in transformation allowed
    • Richter syndrome
    • Other refractory lymphoproliferative diseases


  • ECOG performance status 0-2
  • Creatinine ≤ 2.0 mg/dL

    • Renal dysfunction due to organ infiltration by disease allowed
  • AST and ALT ≤ 3 times upper limit of normal (ULN) (unless due to organ infiltration by disease)
  • Bilirubin ≤ 1.5 times ULN (unless due to Gilbert's syndrome)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No uncontrolled infection
  • No symptomatic coronary artery disease
  • No arrhythmia not controlled by medication
  • No uncontrolled, symptomatic congestive heart failure
  • No myocardial infarction within the past 3 months
  • No other uncontrolled illness
  • No psychiatric illness or social situation that would preclude study compliance


  • At least 2 weeks since prior cytotoxic therapy except in patients with rapidly progressing disease
  • No other concurrent standard or investigational treatment for this cancer
  • No other concurrent cytotoxic investigational drugs
  • No concurrent disulfiram
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00304005

United States, Texas
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
Vion Pharmaceuticals
Study Chair: Bonny L. Johnson, RN, MSN Vion Pharmaceuticals
  More Information Identifier: NCT00304005     History of Changes
Other Study ID Numbers: VION-CLI-041
CDR0000465217 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: March 15, 2006
Last Updated: July 17, 2013

Keywords provided by National Cancer Institute (NCI):
refractory chronic lymphocytic leukemia
recurrent adult diffuse large cell lymphoma
recurrent adult Hodgkin lymphoma

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell processed this record on August 18, 2017